Halozyme Therapeutics, Inc. HALO
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 39.15% | 47.67% | 42.23% | 51.60% | 22.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.15% | 47.67% | 42.23% | 51.60% | 22.12% |
| Cost of Revenue | 52.09% | 67.19% | 65.81% | 77.08% | 6.79% |
| Gross Profit | 35.83% | 42.91% | 34.84% | 44.83% | 26.81% |
| SG&A Expenses | 26.37% | 36.97% | 36.63% | 49.89% | 11.75% |
| Depreciation & Amortization | 66.15% | 66.15% | 66.15% | 31.61% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.23% | 56.84% | 55.84% | 61.11% | 7.45% |
| Operating Income | 35.36% | 42.09% | 30.37% | 44.95% | 33.53% |
| Income Before Tax | 32.73% | 39.02% | 25.38% | -156.59% | 32.58% |
| Income Tax Expenses | -0.35% | 38.24% | 17.66% | -1.12% | 55.43% |
| Earnings from Continuing Operations | 40.99% | 39.21% | 27.06% | -203.34% | 27.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.99% | 39.21% | 27.06% | -203.34% | 27.89% |
| EBIT | 35.36% | 42.09% | 30.37% | 44.95% | 33.53% |
| EBITDA | 37.88% | 44.11% | 34.37% | 43.47% | 30.02% |
| EPS Basic | 45.23% | 44.04% | 32.52% | -211.02% | 38.40% |
| Normalized Basic EPS | 36.94% | 43.84% | 32.31% | 53.71% | 43.48% |
| EPS Diluted | 40.56% | 42.86% | 31.18% | -213.33% | 36.19% |
| Normalized Diluted EPS | 32.64% | 42.40% | 30.75% | 56.83% | 41.04% |
| Average Basic Shares Outstanding | -2.92% | -3.35% | -4.12% | -6.91% | -7.59% |
| Average Diluted Shares Outstanding | 0.23% | -2.37% | -2.98% | -8.77% | -6.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |